¼¼°èÀÇ Ä¸½¶ ³»½Ã°æ ½Ã½ºÅÛ ½ÃÀå
Capsule Endoscope Systems
»óǰÄÚµå : 1513884
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 119 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 6¾ï 1,430¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â 4¾ï 3,120¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 6¾ï 1,430¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â µ¿¾È 5.2%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼ÒÀå ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛÀº CAGR 5.2%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 4¾ï 2,690¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Äµµ ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 1¾ï 1,620¸¸ ´Þ·¯, Áß±¹Àº CAGR 8.6%·Î ¼ºÀå Àü¸Á

¹Ì±¹ ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛ ½ÃÀåÀº 2023³â 1¾ï 1,620¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö ½ÃÀå ±Ô¸ð°¡ 1¾ï 3,400¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â µ¿¾È 8.6%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 1.6%¿Í 5.7%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 2.7%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

ĸ½¶ ³»½Ã°æ(CE)Àº ºñħ½ÀÀûÀÌ°í ³»¾à¼ºÀÌ ÁÁÀº ¹æ¹ýÀ¸·Î ±âÁ¸¿¡ Á¢±ÙÇϱ⠾î·Á¿ü´ø ¼ÒÈ­°üÀ» »ó¼¼ÇÏ°Ô º¼ ¼ö ÀÖ°ÔÇÔÀ¸·Î½á ¼ÒÈ­±â ºÐ¾ß¿¡ Å« ¿µÇâÀ» ¹ÌÃÆÀ¸¸ç, CE°¡ ½ÃÀÛµÈ ÀÌ·¡·Î ¼ÒÀåÀÇ Áø´Ü»Ó¸¸ ¾Æ´Ï¶ó ½Äµµ ¹× °áÀå °Ë»ç±îÁö ¹ßÀüÇØ ¿Ô½À´Ï´Ù. ÀÌ ¹æ¹ýÀº Å©·Ðº´, ºÒ¸íÈ®ÇÑ ¼ÒÈ­°ü ÃâÇ÷, ¼ÒÀå Á¾¾ç µî ´Ù¾çÇÑ ÁúȯÀÇ Áø´Ü¿¡ ¸Å¿ì Áß¿äÇϸç, CE´Â ƯÈ÷ ¼ÒÀåÀÇ º¹ÀâÇÑ ºÎÀ§ÀÇ ¼±¸íÇÑ À̹ÌÁö¸¦ Á¦°øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ ¼ÒÀå ÁúȯÀ» Á¶»çÇÏ´Â µ¥ ÀûÇÕÇÑ ¹æ¹ýÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ÀϹÝÀûÀ¸·Î »óºÎ ¼ÒÈ­°ü ³»½Ã°æ °Ë»ç³ª ÇϺΠ¼ÒÈ­°ü ³»½Ã°æ °Ë»ç µî ±âÁ¸ÀÇ ¹æ¹ýÀ¸·Î °áÁ¤ÀûÀÎ °á°ú¸¦ ¾òÁö ¸øÇÑ °æ¿ì¿¡ Ȱ¿ëµË´Ï´Ù. ƯÁ¤ °íÀ§Ç豺 ȯÀÚÀÇ °æ¿ì ĸ½¶ Àú·ù À§ÇèÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ¼ö¼ú Àü Æò°¡°¡ ±ÇÀåµÇ¸ç, CE¸¦ º¸´Ù ±¤¹üÀ§ÇÑ Áø´Ü ÇÁ·ÎÅäÄÝ¿¡ ½ÅÁßÇÏ°Ô ÅëÇÕÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

CE ±â¼úÀÇ ¹ßÀüÀº Áø´Ü ´É·ÂÀ» Çâ»ó½ÃÄ×À» »Ó¸¸ ¾Æ´Ï¶ó ÀÓ»ó ÀÀ¿ëÀ» È®´ëÇß½À´Ï´Ù. ½Äµµ¿Í ´ëÀå Àü¿ë ĸ½¶ ³»½Ã°æÀÌ °³¹ßµÇ¾î °¢°¢ ¼ÒÈ­°üÀÇ Æ¯Á¤ ºÎÀ§¿¡ ¸Â°Ô °³¹ßµÇ¾ú½À´Ï´Ù. ½Äµµ ĸ½¶³»½Ã°æ °Ë»ç´Â ½Äµµ¿°, ¹Ù·¿½Äµµ µîÀÇ Áø´Ü¿¡ À¯¿ëÇÏÁö¸¸ »ý°Ë ±â´ÉÀÌ ¾ø¾î ±âÁ¸ ³»½Ã°æ °Ë»ç¿¡ ºñÇØ ¹üÀ§°¡ ´Ù¼Ò Á¦ÇÑÀûÀÔ´Ï´Ù. ¹Ý¸é, ´ëÀå ĸ½¶ ³»½Ã°æ °Ë»ç´Â ±âÁ¸ÀÇ ¹æ¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû ¹æ¹ýÀ¸·Î ´ëÀå¾Ï °ËÁøÀ» °­È­ÇÒ ¼ö ÀÖ¾î ±âÁ¸ °Ë»ç¸¦ ²¨¸®´Â ȯÀڵ鿡°Ô ¸Å·ÂÀûÀÏ ¼ö ÀÖ½À´Ï´Ù. ÇâÈÄ Ç¥Àû »ý°Ë ¹× Ä¡·á ÁßÀç°¡ °¡´ÉÇÑ Á¶ÀÛ °¡´ÉÇÑ Ä¸½¶ÀÌ °³¹ßµÇ¸é CEÀÇ ÀÓ»óÀû °¡Ä¡°¡ Å©°Ô Çâ»óµÉ ¼ö ÀÖÀ¸¸ç, °¡±î¿î ½ÃÀÏ ³»¿¡ º¸´Ù ÀÎÅÍ·¢Æ¼ºêÇϰí Á¾ÇÕÀûÀΠĸ½¶ ³»½Ã°æ ±â¼ú·Î ÀüȯµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛÀÇ ½ÃÀå ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù. ¹èÅ͸® ¼ö¸í °³¼±, À̹ÌÁö ǰÁú Çâ»ó, µ¥ÀÌÅÍ Àü¼Û °­È­¿Í °°Àº ±â¼ú ¹ßÀüÀ¸·Î CEÀÇ ÀÓ»ó Àû¿ë°ú È¿´ÉÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ¼­ºñ½º¸¦ °³¼±Çϰí ÁöÃâÀ» ÁÙÀ̸鼭 ÀÇ·áºñ¸¦ Àý°¨ÇÏ´Â ¼¼°è ÀÇ·á ¸ñÇ¥¿¡ µû¶ó ºñ¿ë È¿À²ÀûÀÎ Áø´Ü ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, CE´Â Á¡Á¡ ´õ ¸¹Àº ¼ÒÈ­±â Áúȯ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Áø´Ü ÇÁ·ÎÅäÄÝ¿¡ ÅëÇÕµÇ¾î ±× À¯¿ë¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. µðÁöÅÐ ÀÇ·á ±â·Ï°úÀÇ ÅëÇÕ°ú À̹ÌÁö ºÐ¼®À» À§ÇÑ ÀΰøÁö´ÉÀÇ ¹ßÀüÀº CE¸¦ º¯È­½ÃÄÑ Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚÀÇ ¾ÈÀü°ú ºñħ½ÀÀûÀ̶ó´Â ¾È½É°¨ÀÌ Ä§½ÀÀû ½Ã¼úº¸´Ù CE¸¦ ¼±È£ÇÏ°Ô ¸¸µå´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¼ÒÈ­±â ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó CE¿Í °°Àº È¿°úÀûÀÎ Áø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖÀ¸¸ç, CEÀÇ °³¹ß ¹× äÅÃÀº ±³À° ÇÁ·Î±×·¥, ¼¼°è º¸°Ç ÀÌ´Ï¼ÅÆ¼ºê, ±â¼ú °­È­ ¹× ÀÓ»óÀû äÅÃÀ» °¡¼ÓÈ­Çϱâ À§ÇÑ Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. CE ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ºñħ½ÀÀû ¼ÒÈ­±â Áø´ÜÀÇ ÀçÁ¤ÀÇ¿Í Ä¡·á ´É·ÂÀÇ È®ÀåÀ» ¾à¼ÓÇÏ´Â CE´Â ¼ÒÈ­±â ÁúȯÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â Ãʼ®ÀÌ µÉ °ÍÀÔ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÁÖ¸ñ¹Þ´Â 14°³ ±â¾÷)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Capsule Endoscope Systems Market to Reach US$614.3 Million by 2030

The global market for Capsule Endoscope Systems estimated at US$431.2 Million in the year 2023, is expected to reach US$614.3 Million by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Small Bowel Capsule Endoscope Systems, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$426.9 Million by the end of the analysis period. Growth in the Esophageal Capsule Endoscope Systems segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$116.2 Million While China is Forecast to Grow at 8.6% CAGR

The Capsule Endoscope Systems market in the U.S. is estimated at US$116.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$134.0 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Capsule Endoscope Systems Market - Key Trends and Drivers Summarized

Capsule endoscopy (CE) has significantly impacted the field of gastroenterology by providing a non-invasive, well-tolerated means for detailed visualization of the gastrointestinal tract, areas that were previously difficult to access. Since its inception, CE has advanced beyond small bowel diagnostics to include exploration of the esophagus and colon. This method is crucial for diagnosing various conditions such as Crohn’s disease, obscure gastrointestinal bleeding, and small bowel tumors. CE is particularly valued for its ability to deliver clear images of intricate areas of the small intestine, establishing it as a preferred method for investigating small bowel disorders. The technology is typically utilized when traditional methods such as upper and lower GI endoscopies do not yield conclusive results. For certain high-risk patients, pre-procedural evaluations are recommended to minimize the risk of capsule retention, showcasing the careful integration of CE into broader diagnostic protocols.

Advancements in CE technology have not only refined its diagnostic capabilities but also expanded its clinical applications. Dedicated esophageal and colon capsule endoscopes have been developed, each tailored to specific parts of the gastrointestinal tract. While esophageal capsule endoscopy is valuable for diagnosing conditions like esophagitis and Barrett’s esophagus, it lacks biopsy capabilities, somewhat limiting its scope compared to traditional endoscopy. On the other hand, colon capsule endoscopy presents a non-invasive alternative to conventional methods, potentially enhancing colorectal cancer screening and appealing to patients reluctant to undergo traditional procedures. Looking forward, the potential development of maneuverable capsules capable of targeted biopsy or therapeutic interventions could vastly enhance the clinical value of CE, indicating a shift towards more interactive and comprehensive capsule endoscopy technologies in the near future.

The market growth for capsule endoscopy systems is driven by several factors. Technological advancements such as improved battery life, better image quality, and enhanced data transmission have expanded CE's clinical applications and effectiveness. There's also a growing demand for cost-effective diagnostic methods that align with global healthcare objectives to reduce expenditures while improving care. CE is increasingly integrated into comprehensive diagnostic protocols, extending its utility across more gastrointestinal conditions. The integration with digital health records and advancements in artificial intelligence for image analysis are transforming CE, enhancing diagnostic accuracy and efficiency. Moreover, patient safety and comfort with CE’s non-invasive nature continue to drive its preference over more invasive procedures. As gastrointestinal diseases rise globally, the need for effective diagnostic tools like CE is more pronounced, promoting early and precise diagnoses to improve patient outcomes. The development and adoption of CE are further supported by educational programs, global health initiatives, and strategic collaborations that accelerate technological enhancements and clinical adoption. As CE technologies evolve, they promise to redefine non-invasive gastrointestinal diagnostics and expand therapeutic capabilities, making CE a cornerstone in managing digestive diseases effectively.

Select Competitors (Total 14 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â